Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Screening of FDA Approved Drugs Against COVID-19 Main Protease: Coronavirus Disease

Version 1 : Received: 6 April 2020 / Approved: 6 April 2020 / Online: 6 April 2020 (14:09:04 CEST)

How to cite: Balakrishnan, V.; Lakshminarayanan, K. Screening of FDA Approved Drugs Against COVID-19 Main Protease: Coronavirus Disease. Preprints 2020, 2020040062 (doi: 10.20944/preprints202004.0062.v1). Balakrishnan, V.; Lakshminarayanan, K. Screening of FDA Approved Drugs Against COVID-19 Main Protease: Coronavirus Disease. Preprints 2020, 2020040062 (doi: 10.20944/preprints202004.0062.v1).

Abstract

In the end of December 2019, a new strain of coronavirus was identified in the Wuhan city of Hubei province in China. Within a shorter period of time, an unprecedented outbreak of this strain was witnessed over the entire Wuhan city. This novel coronavirus strain was later officially renamed as COVID-19 (Coronavirus disease 2019) by the World Health Organization. The mode of transmission had been found to be human-to-human contact and hence resulted in a rapid surge across the globe where more than 1,100,000 people have been infected with COVID-19. In the current scenario, finding potent drug candidates for the treatment of COVID-19 has emerged as the most challenging task for clinicians and researchers worldwide. Identification of new drugs and vaccine development may take from a few months to years based on the clinical trial processes. To overcome the several limitations involved in identifying and bringing out potent drug candidates for treating COVID-19, in the present study attempts were made to screen the FDA approved drugs using High Throughput Virtual Screening (HTVS). The COVID-19 main protease (COVID-19 Mpro) was chosen as the drug target for which the FDA approved drugs were initially screened with HTVS. The drug candidates that exhibited favorable docking score, energy and emodel calculations were further taken for performing Induced Fit Docking (IFD) using Schrodinger’s GLIDE. From the flexible docking results, the following four FDA approved drugs Sincalide, Pentagastrin, Ritonavir and Phytonadione were identified. In particular, Sincalide and Pentagastrin can be considered potential key players for the treatment of COVID-19 disease.

Subject Areas

COVID-19; FDA approved drugs; High Throughput Virtual Screening; Sincalide; Pentagastrin.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.